Currently approved prophylactic HPV vaccines

Expert Review of Vaccines

Volumn 8, Issue 12, 2009, Pages 1663-1679

  Harper, Diane M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical cancer; Efficacy; HPV; Immunogenicity; Safety

Indexed keywords

ALUMINUM HYDROXIDE; PLACEBO; WART VIRUS VACCINE;

ADENOCARCINOMA; ADJUVANT THERAPY; ARTHRALGIA; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; IMMUNOGENICITY; MYALGIA; NONHUMAN; PAIN; PAPILLOMATOSIS; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SQUAMOUS CELL CARCINOMA; SWELLING; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS AS TOPIC; CONDYLOMATA ACUMINATA; DRUG APPROVAL; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 73849109445     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.123     Document Type: Review

References (77)

1. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 90 (2007).
2. zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res. 36(2 pt 2), 794 (1976).
3. Meisels A, Fortin R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol. 20(6), 505-509 (1976).
4. Meisels A, Fortin R, Roy M. Condylomatous lesions of the cervix. II. Cytologic, colposcopic and histopathologic study. Acta Cytol. 21(3), 379-390 (1977).
5. zur Hausen H. The search for infectious causes of human cancers: where and why (Nobel lecture). Angew. Chem. Int. Ed. Engl. 48(32), 5798-5808 (2009). •• Nobel lecture by zur Hausen.
6. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell. 5(3), 557-567 (2000).
7. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. In: IARC Cancer Base 5 version 2.0. IARC Press, Lyon, France (2004).
8. Doerfler D, Bernhaus A, Kottmel A, Sam C, Koelle D, Joura EA. Human papillomavirus infection prior to coitarche. Am. J. Obstet. Gynecol. 200(5), 487.e1-487e.5 (2009). • Documents the prevalence of oncogenic human papillomavirus (HPV) in children.
9. Dunne EF, Karem KL, Sternberg MR et al. Seroprevalence of human papillomavirus type 16 in children. J. Infect. Dis. 191, 1817-1819 (2005). • Documents the prevalence of oncogenic HPV in children.
10. Stone KM, Karem KL, Sternberg MR et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J. Infect. Dis. 186, 1396-1402 (2002). • Documents the prevalence of oncogenic HPV in children.
11. Schiffman MH, Bauer HM, Hoover RN et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl Cancer Inst. 85(12), 958-964 (1993).
12. Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69(6), 3959-3963 (1995).
13. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/ aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33-34), 5937-5949 (2006).
14. Caulfield MJ, Shi L, Wang S et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum. Vaccine 3(4), 139-145 (2007).
15. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet (2009) (Epub ahead of print). • Documents the 6.4 years of efficacy for Cervarix® .
16. Villa LL, Costa RLR, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95, 1459-1466 (2006). • Documents the 5-year efficacy of Gardasil® .
17. Koutsky LA, for the FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1915-1927 (2007). •• Pivotal article supporting the claims for Gardasil.
18. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356, 1928-1943 (2007).
19. Brown DR, Kjaer SK, Sigurdson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199, 926-935 (2009). • Documents the cross-protection of Gardasil in the naive per-protocol population.
20. Wheeler CM, Kjaer SK, Sigurdson K et al. The impact of quadrivalent human papillomavirus (HPV types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 199, 936-944 (2009).
21. Herrero R, Hildesheim A, Rodriguez AC et al. Rationale and design of a communitybased double blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 26, 4795-4808 (2008).
22. Lehtinen M, Apter D, Dubin G et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int. J. STD AIDS 17, 517-521 (2006).
23. Liaw K, Dillner J, Kjaer S et al. Evaluating qHPV vaccine impact in the general female population in Iceland, Sweden, Denmark, Norway. Presented at: 25th International Papillomavirus Conference. Malmo, Sweden, 8-12 May 2009 (Poster P-01.11).
24. Hildesheim A. Herrero R. Wacholder S et al.; Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298(7), 743-753 (2007). •• Shows conclusively that the prophylactic vaccines cannot change the course of HPV disease once HPV has infected the basal cell.
25. Rodriguez AC, Kreimer AR, Wacholder S et al. Imputed global vaccination benefit by key risk predictors. Presented at: 25th International Papillomavirus Conference. Malmo, Sweden, 8-12 May 2009 (Abstract O-01.05).
26. Paavonen J, Naud P, Salmerón J. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374, 301-314 (2009). •• Pivotal study upon which the claims for Cervarix are supported.
27. Herrero R. Human Papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J. Infect. Dis. 199, 919-922 (2009). • Provides cogent logic in how to interpret cross-protection efficacies.
28. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol. Oncol. 110(3 Suppl. 1), S18-S25 (2008). • Provides cogent logic in how to interpret cross-protection efficacies.
29. Wentzensen N, Schiffman M, Dunn T et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int. J. Cancer 125, 2151-2158 (2009).
30. Olsson S-E et al. Impact of HPV 6/11/16/18 vaccine on abnormal Pap tests and procedures. Presented at: 25th International Papillomavirus Conference. Malmo, Sweden, 8-12 May 2009 (Abstract O-01.08).
31. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am. J. Obstet. Gynecol. 191, 105-113 (2004).
32. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 324, 17-27 (2004).
33. Giuliano A, Palefsky J; on behalf of the male quadrivalent HPV vaccine efficacy trial study group. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men. Presented at: European Research Organization on Genital Infection and Neoplasia International Multidisciplinary Conference. Nice-Acropolis, France, 12-15 November 2008 (Abstract SS 19-7).
34. Smith JS, Backes DM, Hoots BE et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet. Gynecol. 113(4), 917-924 (2009).
35. Winer RL, Hughes JP, Feng Q et al. Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. J. Infect. Dis. 199, 815-818 (2009).
36. Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369, 1693-1702 (2007).
37. Gunther OP, Ogilvie G, Naus M. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity? J. Infect. Dis. 197, 1653-1661 (2008). •• Comprehensive cost analysis showing several possible outcomes given parameter variability.
38. Barnabas RV, Laukkanen P, Koskela P et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 3(5), e138 (2006). 39 Goldie SJ, O'Shea M, Campos NG et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVIeligible countries. Vaccine 26, 4080-4093 (2008).
39. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359, 821-832 (2008).
40. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. Br. Med. J. 337, a769 (2008).
41. Goldhaber-Fiebert JD, Stout NK, Salomon JA et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J. Natl Cancer Inst. 100, 308-302 (2008).
42. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg. Infect. Dis. 14, 244-251 (2008).
43. Rogstad KE. The psychological impact of abnormal cytology and colposcopy. Br. J. Obstet. Gynecol. 109(4), 364-368 (2002). • Presents the most up-to-date information on the risks from deep excisional therapy and the psychosocial disutilities experienced from cervical cancer screening.
44. Prendiville W. The treatment of CIN: what are the risks? Cytopathology 20(3), 145-153 (2009). • Presents the most up-to-date information on the risks from deep excisional therapy and the psychosocial disutilities experienced from cervical cancer screening.
45. Schwarz TF, Spaczynski M, Schneider A et al.; HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 27(4), 581-587 (2009).
46. Joura EA, Kjaer SK, Wheeler CM et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26(52), 6844-6851 (2008).
47. Einstein MH, Baron M, Levin MJ et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccine 5(10), 1-15 (2009). • Describes the immunologic evaluation at 7 months postvaccination series for both vaccines measured in the same systems.
48. Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J. Obstet. Gynaecol. Res. 33(2), 103-113 (2007).
49. Olsson SE, Villa LL, Costa RLR et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25, 4931-4939 (2007).
50. Pedersen C, Petaja T, Strauss G et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health 40, 564-571 (2007).
51. Reisinger KS, Block SL, Lazcano-Ponce E et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr. Infect. Dis. J. 26, 201-209 (2007).
52. Petaja T, Keranen H, Karppa T et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J. Adolesc. Health 44, 33-40 (2009).
53. Block SL, Nolan T, Sattler C et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118, 2135-2145 (2006).
54. Kahn JA, Cooper HP, Vadaparampil ST et al. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians. Cancer Epidemiol. Biomarkers Prev. 18(8), 2325-2332 (2009).
55. Poland GA, Ovsyannikova IG, Jacobson RM. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr. Infect. Dis. J. 28, 431-432 (2009). • Addresses the need to identify those who are most at risk for vaccine adverse events.
56. Slade BA, Leidel L, Vellozzi C et al. Postlicensure safety surveillance for qHPV recombinant vaccine. JAMA 302(7), 750-757 (2009).
57. Brotherton JM, Gold MS, Kemp AS et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 179, 525-533 (2008).
58. Kang LW, Crawford N, Tang ML et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. Br. Med. J. 337, a2642 (2008).
59. CDC. Syncope after vaccination - United States, January 2005-July 2007. MMWR Morb. Mortal. Wkly Rep. 57, 457-460 (2008).
60. Marsee DK, Williams JM, Velazquez EF. Aluminum granuloma after administration of the quadrivalent human papillomavirus vaccine. Report of a case. Am. J. Dermatopathol. 30, 622-624 (2008).
61. Studdiford J, Lamb K, Horvath K et al. Development of unilateral cervical and supraclavicular lymphadenopathy after human papillomavirus vaccination. Pharmacotherapy 28(9), 1194-1197 (2008).
62. Debeer P, De Munter P, Bruyninckx F, Devlieger R. Brachial plexus neuritis following HPV vaccination. Vaccine 26, 4417-4419 (2008).
63. Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination. Med. J. Aust. 189, 178 (2008).
64. Lower J. Two unclear cases of death. Can we still recommend HPV vaccination? MMW Fortschritte der Medizin 150(8), 6 (2008).
65. Lawrence G, Gold MS, Hill R et al. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun. Dis. Intell. 32, 371-387 (2008).
66. Wildemann B, Jarius S, Hartmann M et al. Acute disseminated encephalomyelitis following vaccination against human papillomavirus. Neurology 72, 2132-2133 (2009).
67. Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult. Scler. 15(1), 116-119 (2009).
68. Stokley S, Dorell C, Yankey D. National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2008. MMWR Morb. Mortal. Wkly Rep. 58, 997-1001 (2009).
69. Munoz N, Manalastas R, Pitisuttithum P et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus recombinant vaccine in women aged 24-45 years: a randomised, double blind trial. Lancet 373, 1949-1957 (2009).
70. Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of CIN. Br. Med. J. 331, 1183-1185 (2005).
71. Edgren G, Sparén P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 8(4), 311-316 (2007). • Reports from a very large cohort study on the second wave of disease caused by latent HPV infections. This level of disease must be considered in the programmatic logistics of screening and vaccination.
72. Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. Public Health Genomics 12, 319-330 (2009).
73. de Sanjosé S, Diaz M, Castellsagué X et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 7, 453-459 (2007).
74. Romanowski B, de Borba PC, Naud PS et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet (2009) (In press).
75. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet. Gynecol. 94, 307-310 (1999).
76. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
77. Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: A literature review. Vaccine 26, 6258-6265 (2008).